Summary: The role of Vitamin D in COVID-19 has been clarified by the VIVID Trial, one of the largest randomized studies to date. Investigators report that high‑dose vitamin D3 did not reduce the severity of acute COVID‑19 or the need for hospitalization, but the trial uncovered a promising signal that supplementation may lower the risk of Long COVID, particularly persistent cognitive and physical symptoms such as brain fog and fatigue.
Participants who adhered to the vitamin D regimen reported fewer lingering symptoms eight weeks after infection, suggesting that while vitamin D is not a cure for acute SARS‑CoV‑2 infection, it could influence recovery and reduce long‑term neurological and systemic effects.
Key facts
- No acute impact: Daily high‑dose vitamin D3 (3,200 IU/day after a short loading dose) did not lower the risk of hospitalization, death, or symptom severity during the first four weeks following infection.
- Signal for Long COVID: Among participants who followed the protocol, 21% in the vitamin D group reported at least one persistent symptom at eight weeks versus 25% in the placebo group, indicating a potentially meaningful reduction in long‑term symptoms.
- Rigorous design: The VIVID Trial enrolled 1,747 adults with recent COVID‑19 across the United States and Mongolia and randomized participants with stratification for vaccination status, BMI, age, sex, and other factors.
Source: Mass General Brigham
“There has been tremendous interest in whether vitamin D supplements can help with COVID‑19,” said JoAnn Manson, MD, DrPH, of the Mass General Brigham Department of Medicine, senior author of the study. “Although we did not find a reduction in acute disease severity or hospitalizations, we observed a promising signal that vitamin D may reduce the risk of Long COVID—an outcome that deserves further research.”
Study design and participants
The Vitamin D for COVID‑19 (VIVID) Trial was a randomized, double‑blind, placebo‑controlled study conducted in the U.S. (December 2020–September 2022) and Mongolia (September 2021–April 2022). The trial enrolled 1,747 adults who recently tested positive for SARS‑CoV‑2 and 277 household contacts. Index participants and up to one cohabiting contact were cluster randomized to receive either a short oral loading dose of vitamin D3 (9,600 IU/day for two days) followed by 3,200 IU/day for four weeks, or matching placebo.
Median time from positive test to start of supplementation was three days. Investigators used stratified randomization and statistical weighting to balance key variables—age, sex, BMI, race/ethnicity, and COVID‑19 vaccination status—between treatment arms.
Primary outcomes and safety
The primary outcome measured whether index participants had one or more healthcare visits (including hospitalization), or death, within four weeks. The trial found no significant difference between the vitamin D and placebo groups for healthcare utilization or death during the acute phase: cumulative incidences were 0.28 for the vitamin D group and 0.29 for placebo (odds ratio 0.97; 95% CI: 0.75–1.24). Symptom severity scores and the rate of household transmission also did not differ meaningfully between groups.
No safety concerns were identified with the dosing regimen used in this trial.
Long COVID findings
While the primary acute outcomes were negative, per‑protocol analyses showed a trend toward reduced prevalence of Long COVID at eight weeks among participants who adhered to vitamin D supplementation. In the adherent subset, 21% of vitamin D recipients reported at least one persistent symptom at eight weeks versus 25% of placebo participants (OR 0.78; 95% CI: 0.59–1.03). The difference was of borderline statistical significance but points to a clinically relevant effect on lingering fatigue, brain fog, and related cognitive complaints.
The authors emphasize that this represents an encouraging signal rather than definitive evidence. They call for larger trials and longer follow‑up to confirm whether routine vitamin D supplementation can prevent Long COVID or reduce its severity.
Practical considerations
The dose used in VIVID (3,200 IU/day after a two‑day loading dose) exceeds typical daily recommendations and was administered under trial conditions. Researchers caution against starting high‑dose supplementation without medical guidance and further confirmation from larger studies.
Authorship and disclosures
Lead investigators include JoAnn Manson, Davaasambuu Ganmaa, Kaitlyn Cook, and colleagues from Mass General Brigham and partner institutions. Other contributors listed in the study include Allison Clar, Michael Rueschman, Aditi Hazra, Howard D. Sesso, Valerie E. Stone, Patricia Copeland, Georgina Friedenberg, Polyna Khudyakov, Dorjbal Enkhjargal, Tsolmon Bilegtsaikhan, Kenneth H. Mayer, Raji Balasubramanian, Douglas C. Smith, Quanhong Lei, Todd Lee, Emily G. McDonald, Tserenkhuu Enkhtsetseg, Erdenebaatar Sumiya, Yansanjav Narankhuu, Myagmarsuren Erdenetuya, Dalkh Tserendagva, Rikard Landberg, Niclas Roxhed, Susanne Rautiainen, and others.
Disclosures note that one author, Niclas Roxhed, is a founder and shareholder of a company that commercialized the blood collection device used in the study; other authors report no conflicts of interest. The study received philanthropic and in‑kind support, including donated capsules for the trial.
Conclusions
The VIVID Trial found that high‑dose vitamin D3 supplementation did not reduce short‑term healthcare utilization or acute COVID‑19 severity. However, an encouraging signal for reduced Long COVID symptoms among adherent participants suggests a possible role for vitamin D in post‑infection recovery. Additional large, well‑powered trials are needed to confirm these findings and to determine whether vitamin D could become a preventive strategy against persistent post‑COVID symptoms.
Frequently asked questions
Q: Can vitamin D prevent infection or severe COVID‑19?
A: In this trial, vitamin D did not prevent infection nor reduce acute severity or hospitalizations.
Q: Does vitamin D help with brain fog?
A: The trial observed fewer persistent cognitive and physical symptoms at eight weeks among those who adhered to supplementation, suggesting a potential neuroprotective or anti‑inflammatory effect during recovery.
Q: Should I start taking high doses of vitamin D now?
A: The VIVID Trial used doses above usual daily allowances and was conducted under clinical oversight. The results are promising but not definitive, and individuals should consult healthcare providers before starting high‑dose supplementation.
Research citation: A Randomized Trial of Vitamin D Supplementation and COVID‑19 Clinical Outcomes and Long COVID: The VIVID Trial. Journal of Nutrition. DOI: 10.1016/j.tjnut.2026.101398. Registered at clinicaltrials.gov as NCT04536298.